Because adiponectin has a causal role in the progression of metabolic syndrome, DM, CAD and atherosclerosis, several trials using adiponectin as a therapeutic agent have been undertaken [26, –28]. This evidence concerns the gene ADIPOQ and metabolic syndrome.